Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free SCNI Stock Alerts

Scinai Immunotherapeutics (SCNI) Competitors

Scinai Immunotherapeutics logo
$0.24 +0.00 (+1.04%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.24 0.00 (-0.21%)
As of 08/14/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SCNI vs. AQB, ERNA, MBIO, RNAZ, and CLGN

Should you buy Scinai Immunotherapeutics stock or one of its competitors? Scinai Immunotherapeutics's main competitors and comparable companies include AquaBounty Technologies (AQB), Ernexa Therapeutics (ERNA), Mustang Bio (MBIO), TransCode Therapeutics (RNAZ), and CollPlant Biotechnologies (CLGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scinai Immunotherapeutics compare to AquaBounty Technologies?

Scinai Immunotherapeutics (NASDAQ:SCNI) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than AquaBounty Technologies. MarketBeat recorded 6 mentions for Scinai Immunotherapeutics and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.94 beat Scinai Immunotherapeutics' score of 0.63 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scinai Immunotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AquaBounty Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Scinai Immunotherapeutics' return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
AquaBounty Technologies N/A -147.07%-28.73%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AquaBounty Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Scinai Immunotherapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Scinai Immunotherapeutics has higher earnings, but lower revenue than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.96-$8.31M-$1.06N/A
AquaBounty Technologies$2.47M3.10-$18.49M-$0.82N/A

Summary

Scinai Immunotherapeutics beats AquaBounty Technologies on 8 of the 12 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Ernexa Therapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for Scinai Immunotherapeutics and 2 mentions for Ernexa Therapeutics. Scinai Immunotherapeutics' average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.51 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scinai Immunotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ernexa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Scinai Immunotherapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
Ernexa Therapeutics N/A -305.93%-169.86%

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 602.58%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Scinai Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Scinai Immunotherapeutics has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.96-$8.31M-$1.06N/A
Ernexa TherapeuticsN/AN/A-$14.08M-$14.35N/A

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Mustang Bio?

Mustang Bio (NASDAQ:MBIO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mustang Bio has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

In the previous week, Scinai Immunotherapeutics had 5 more articles in the media than Mustang Bio. MarketBeat recorded 6 mentions for Scinai Immunotherapeutics and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.87 beat Scinai Immunotherapeutics' score of 0.63 indicating that Mustang Bio is being referred to more favorably in the media.

Company Overall Sentiment
Mustang Bio Very Positive
Scinai Immunotherapeutics Positive

Scinai Immunotherapeutics' return on equity of 0.00% beat Mustang Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang BioN/A -34.23% -17.55%
Scinai Immunotherapeutics N/A N/A N/A

Mustang Bio has higher earnings, but lower revenue than Scinai Immunotherapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$1.92M-$0.45N/A
Scinai Immunotherapeutics$1.31M0.96-$8.31M-$1.06N/A

Summary

Scinai Immunotherapeutics beats Mustang Bio on 8 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than TransCode Therapeutics. MarketBeat recorded 6 mentions for Scinai Immunotherapeutics and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.48 beat Scinai Immunotherapeutics' score of 0.63 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TransCode Therapeutics Positive
Scinai Immunotherapeutics Positive

Scinai Immunotherapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TransCode TherapeuticsN/A -875.35% -50.36%
Scinai Immunotherapeutics N/A N/A N/A

Scinai Immunotherapeutics has higher revenue and earnings than TransCode Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A
Scinai Immunotherapeutics$1.31M0.96-$8.31M-$1.06N/A

TransCode Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats TransCode Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to CollPlant Biotechnologies?

Scinai Immunotherapeutics (NASDAQ:SCNI) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scinai Immunotherapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Scinai Immunotherapeutics' return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Scinai ImmunotherapeuticsN/A N/A N/A
CollPlant Biotechnologies -683.68%-218.81%-139.28%

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,388.02%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Scinai Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CollPlant Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Scinai Immunotherapeutics has higher earnings, but lower revenue than CollPlant Biotechnologies. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scinai Immunotherapeutics$1.31M0.96-$8.31M-$1.06N/A
CollPlant Biotechnologies$2.37M2.01-$11.49M-$1.45N/A

Scinai Immunotherapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 6 mentions for Scinai Immunotherapeutics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.94 beat Scinai Immunotherapeutics' score of 0.63 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scinai Immunotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CollPlant Biotechnologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Scinai Immunotherapeutics beats CollPlant Biotechnologies on 9 of the 16 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCNI vs. The Competition

Export
MetricScinai ImmunotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.25M$3.72B$7.03B$13.07B
Dividend YieldN/A3.69%2.57%10.65%
P/E Ratio-0.2310.77271.2625.38
Price / Sales0.961,367.36623.44105.58
Price / CashN/A101.4275.7053.27
Price / Book0.3116.7812.926.21
Net Income-$8.31M-$13.32M$3.45B$347.71M
7 Day Performance-1.14%1.76%1.16%1.08%
1 Month Performance-4.53%2.86%2.17%1.87%
1 Year Performance-84.75%54.10%62.38%20.79%

Scinai Immunotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCNI
Scinai Immunotherapeutics
1.2653 of 5 stars		$0.24
+1.0%		N/A-84.7%$1.25M$1.31MN/A20
AQB
AquaBounty Technologies
0.3222 of 5 stars		$1.07
+8.1%		N/A+106.3%$5.10M$2.47MN/A100
ERNA
Ernexa Therapeutics
2.2928 of 5 stars		$4.36
+6.3%		$30.00
+588.1%		-89.2%$4.78MN/AN/A10
MBIO
Mustang Bio
1.3224 of 5 stars		$0.58
-3.6%		N/A-66.5%$4.52MN/AN/A100
RNAZ
TransCode Therapeutics
1.2189 of 5 stars		$4.27
+0.5%		N/A-69.6%$4.50MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
The Greatest Wealth Transfer Since the Internet Boom Just Started
Wall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...
Altimetry | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel